Drug Type Antibody drug conjugate (ADC) |
Synonyms 重组HER2人源化单克隆抗体单甲基奥瑞他汀F偶联剂, FS-1502, IKS 014 + [4] |
Target |
Mechanism HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists), Tubulin inhibitors |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic human epidermal growth factor 2 positive carcinoma of breast | Phase 3 | CN | 28 Mar 2023 | |
Metastatic Colorectal Carcinoma | Phase 3 | CN | 30 Jan 2023 | |
Non-Small Cell Lung Cancer | Phase 3 | CN | 30 Jan 2023 | |
Stomach Cancer | Phase 3 | CN | 30 Jan 2023 | |
Breast Cancer | Phase 3 | CN | - | |
HER2-positive gastric cancer | Phase 2 | CN | 08 Nov 2022 | |
HER2 Positive Solid Tumors | Phase 2 | CN | 14 Jun 2022 | |
RAS/BRAF Wild Type HER2 Positive Colorectal Cancer | Phase 2 | CN | 07 Jun 2022 | |
Gastroesophageal junction adenocarcinoma | Phase 2 | CN | 31 May 2022 | |
HER2 mutant non-small cell lung cancer | Phase 2 | CN | 18 Mar 2022 |
NCT03944499 (Pubmed) Manual | Phase 1 | 150 | (HER2-expressing solid tumors (n = 5) and BC (n = 145)) | vbsrupidki(wlceyrcqgs) = udqodeyrpb tcnwooekmt (hbzjjvktnw ) View more | Positive | 17 Jun 2024 | |
(HER2-positive BC patients receiving the RP2D) | yrgghokbkh(bupfvrhjyq) = nxlemxhhya gfjjqzcajj (byxagwlkbv ) View more | ||||||
NCT03944499 (ASCO2023) Manual | Phase 1 | Advanced HER2-Positive Breast Carcinoma HER2 Positive | 70 | psypensdcp(dxsyenuthd) = inywmhohoj okwyhddqbu (pvbymskowq, 40.45 - 65.17) View more | Positive | 26 May 2023 |